Cerus Corporation
Cerus Corporation (CERS)
Overview
Cerus Corporation is a Concord, California-based biomedical products company that develops and commercializes the INTERCEPT Blood System, a pathogen-reduction technology used by blood collection organizations to inactivate viruses, bacteria, parasites, and white blood cells in donated blood components before transfusion. Founded in 1997 and incorporated in Delaware with a European subsidiary (Cerus Europe B.V.) in the Netherlands, Cerus reported trailing-twelve-month revenue of about $221.6 million and a market capitalization of roughly $516 million as of September 2026, with 275 employees. The company holds 16 issued or allowed U.S. patents and roughly 166 foreign patents covering INTERCEPT technology, expiring between 2025 and 2042, and continues to invest in expanding its approved product line, including an in-development system for red blood cells.
What They Do & How They Make Money
Cerus makes money by selling INTERCEPT Blood System kits and associated illuminator equipment to blood collection organizations and hospitals, who use the technology to treat donated platelets, plasma, and cryoprecipitate with proprietary compounds (amotosalen for platelets/plasma, amustaline in development for red blood cells) that, activated by UV light, bind to pathogen nucleic acid and render it non-infectious while preserving the blood product's therapeutic properties. Its three commercialized product lines — INTERCEPT for Platelets, INTERCEPT for Plasma, and INTERCEPT for Cryoprecipitation (FDA-approved November 2020, including production of INTERCEPT Fibrinogen Complex) — are sold directly in the U.S. and parts of Europe, through Cerus Europe in the EU/CIS/Middle East, and via distributors elsewhere, plus a China joint venture (Cerus Zhongbaokang) exploring local development. Government contracts with BARDA, the FDA, and the Department of Defense supplement commercial sales, particularly around biodefense and military blood-supply applications. The company's manufacturing depends on a small set of long-term sole-source suppliers — Fresenius Kabi (disposable kits, through 2031), Porex (adsorption devices, through 2027), and Piramal (amotosalen compound) — a concentration that is both an operating risk and, once qualified, a barrier that raises switching costs for potential new entrants.
Competitors
- Grifols, Octapharma AG, and MacoPharma International in Europe, offering competing or alternative pathogen-reduction and plasma-treatment technologies.
- Terumo BCT, which has received CE Mark approval for platelet and plasma pathogen reduction, representing Cerus's most direct emerging European competitor.
- Kedrion Biopharma and other blood-product processors in select international markets.
- Alternative pathogen-detection/testing companies whose screening approaches compete for blood-safety budget dollars as a substitute to pathogen inactivation.
- In the U.S., Cerus states it is currently the only FDA-approved pathogen-reduction product for platelets, a significant near-term competitive advantage, though Octapharma offers a competing treated-plasma product.
Competitive Position
Cerus's core strength is regulatory: pathogen-reduction technology for blood products requires lengthy, expensive FDA and international approval processes, and Cerus is currently the sole FDA-approved platelet pathogen-reduction system in the U.S. — a structural barrier that keeps competitors like Terumo BCT largely confined to Europe for now. Its blood-center customer base (anchored by relationships with the American Red Cross, France's EFS, and England's NHSBT) is highly concentrated but also highly sticky once a blood center adopts INTERCEPT, since switching pathogen-reduction systems requires new regulatory validation, staff retraining, and supply-chain requalification — none of which blood centers undertake casually given patient-safety stakes. The extensive patent estate (182 combined U.S./foreign patents) further reinforces this position through the 2030s. The main risks are customer concentration (a handful of national blood-collection organizations drive most revenue, and the EFS France contract's status matters materially), continued reliance on Fresenius Kabi and other sole-source manufacturing partners, and management's own acknowledgment that "contribution margins from our sales is likely to be less than the cost of our operating expenses," meaning substantial revenue growth is still needed to reach sustained profitability. Long-term upside depends on FDA approval of the red blood cell system (RedeS Phase 3 study) and continued international expansion of the approved platelet, plasma, and cryoprecipitation lines.